← Research ProtocolsSurvodutide
STUDIED EXPOSURE MAP / 2024
Survodutide
tested in research.
The actual doses, concentrations or exposure levels reported by the source — kept attached to route, population, timeframe and evidence type.
HUMAN / RANDOMIZED PHASE 2NEW ENGLAND JOURNAL OF MEDICINESTUDIED EXPOSURE ≠ RECOMMENDED DOSE
STUDIED EXPOSURE / SOURCE DATANumbers below describe this research source only.
2.4 mg
SC · once weekly target
4.8 mg
SC · once weekly target
6.0 mg
SC · once weekly target
Context: These are target doses in a liver-disease trial with an escalation phase. Population, route and disease context are inseparable from the numbers.
NOT A DOSING GUIDEENHANCED is reporting what researchers administered or tested. It does not convert these numbers into a personal dose, reconstitution plan, cycle, titration schedule or recommendation.
SOURCE / NEW ENGLAND JOURNAL OF MEDICINE
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Study design and tested exposure are separated from recommendation. Route and population stay visible so the numbers cannot be read without context.
2024
01 / DESIGNPhase 2 · randomized · placebo-controlled
02 / POPULATION / MODELAdults with biopsy-confirmed MASH and fibrosis F1–F3
03 / ROUTESubcutaneous · once weekly
04 / TIMEFRAME48 weeks · 24-week escalation + 24-week maintenance
05 / PRIMARY QUESTIONHistologic improvement in MASH without worsening fibrosis
It supports a factual statement about the exposure tested in this research source. It does not establish that the same exposure is appropriate, effective or safe outside that source.
Broader research index. This entity is not presented here as an ENHANCED catalogue compound.
Study exposure ≠ personal protocol. Animal doses are never converted to human-equivalent amounts here. IV, topical, oral, intranasal and subcutaneous exposures are not treated as interchangeable.